Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Tools for ADC PK Analysis——Anti-payload antibodies

Tools for ADC PK Analysis——Anti-payload antibodies

Tools for ADC PK Analysis——Anti-payload antibodies
Background
Product List
Supplemental Data
Related Products
Product Features
High Purity (>90%)
High affinity and specificity validated
High sensitivity verified by ADCs binding assay
Complete technical support solution
Click here to view data >>
Research Applications
ELISA PK/PD studies on ADCs in preclinical and clinical
DAR value detection
Background
Characterizing biological drugs is a critical step throughout the drug development process, starting from development to clinical evaluation.
Antibody-drug conjugates (ADCs) have a complex and varied structure. With the addition of matrix complexity and species, DAR and PK/PD studies need to be comprehensively evaluated for each component. Each of ADC's component having different gold standards for characterization. This includes utilizing analytical methods such as ELISAs and LC-MS.
TypeAnalyte DetailTypical Method
Total AntibodyConjugated, partially unconjugated, and fully unconjugated (DAR > 0)Ligand Binding Assay
Conjugated AntibodyAntibody with minimum DAR > 1Ligand Binding Assay
Antibody-conjugated DrugTotal small-molecule drug conjugated to AntibodyAffinity LC-MS / Ligand Binding Assay
Unconjugated DrugSmall molecule drug not conjugated to antibodyLC-MS
Total DrugTotal unconjugated and conjugated DrugLC-MS

ADC molecule type and typical analytical methods for evaluation. 1

Different LBA formats to analyze ADCs in serum

Different LBA formats to analyze ADCs in serum 2

To assist with your PK studies when evaluating your ADCs, ACROBiosystems now offer several anti-payload antibodies with a high affinity that bind specifically to DM-1, DXD, SN38, MMAE, and more! Don’t forget, we also offer HRP-conjugated anti-MMAE antibodies to eliminate the need for a secondary antibody!
Product List
MoleculeCat. No.Product DescriptionPreorder/Order
Great news! More high-quality anti-payload antibodies are coming soon from ACROBiosystems. If you have any suggestions or custom requirements, please click here to contact us.

Supplemental Data
High purity verified by SEC-MALS
High purity verified by SEC-MALS

The purity of Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) is more than 90% and the molecular weight of this protein is around 134-163 kDa verified by SEC-MALS.

High affinity binding to MMAE-ADC validated
High affinity binding to MMAE-ADC validated

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).

High affinity binding to MMAE-ADC validated

Immobilized Disitamab Vedotin at 1 μg/mL (100 μL/well) can bind HRP conjugated Anti-MMAE Antibody, mAb (Cat. No. MME-PLS104) with a linear range of 0.5-16 ng/mL (QC tested).

High affinity binding to PTX-ADC validated
High affinity binding to PTX-ADC validated

Immobilized ADC-PTX at 1 μg/mL (100 μL/well) can bind Mouse Anti-PTX Antibody, Mouse IgG2a (MALS verified) (Cat. No. PTX-S343) with a linear range of 0.106-6.767 ng/mL (QC tested).

Related Products

The key reagents to the evaluation of ADC immunogenicity - Anti-idiotypic antibodies
MoleculeCat. No.Product DescriptionNeutralizing activityApplication
Adalimu*abADB-Y19Anti-Adalimu*ab Antibodies (AY19)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Adalimu*abADB-Y23bAnti-Adalimu*ab Antibodies (AY23b) (recommended for PK/PD)Non-Neutralizing AntibodyPK bridging ELISA; Indirect ELISA
Bevacizu*abBEB-Y10Anti-Bevacizu*ab Antibodies (AY10) (MALS verified, recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA; Neutralizing assay; Indirect ELISA
Bevacizu*abBEB-Y12Anti-Bevacizu*ab Antibodies (AY12) (recommended for neutralizing assay)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*abBEB-Y9Anti-Bevacizu*ab Antibodies (AY9) (recommended for ADA assay)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*abBEB-BY13Biotinylated Anti-Bevacizu*ab Antibodies (AY13) (recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA;Neutralizing assay; Indirect ELISA
Cetuxi*abCEB-Y27Anti-Cetuxi*ab Antibodies (AY27) (recommended for ADA assay)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*abCEB-Y31Anti-Cetuxi*ab Antibodies (AY31) (Non-Neutralizing)Non-Neutralizing AntibodyADA assay; Indirect ELISA
Cetuxi*abCEB-Y28Anti-Cetuxi*ab Antibodies (AY28)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*abCEB-BY31Biotinylated Anti-Cetuxi*ab Antibodies (AY31) (recommended for PK/PD)Non-Neutralizing AntibodyPK bridging ELISA; Indirect ELISA
Rituxi*abRIB-Y36Anti-Rituxi*ab Antibodies (AY36) (recommended for ADA assay)Neutralizing AntibodyADA assay;Neutralizing assay; Indirect ELISA
Rituxi*abRIB-Y37Anti-Rituxi*ab Antibodies (AY37) (recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA;Neutralizing assay;Indirect ELISA
Rituxi*abRIB-Y35cAnti-Rituxi*ab Antibodies (MALS verified)Non-Neutralizing AntibodyADA assay; Indirect ELISA
Trastuzu*abTRB-Y5bAnti-Trastuzu*ab Antibodies (AY5b) (recommended for PK/PD)Non-Neutralizing AntibodyNeutralizing Antibody
Trastuzu*abTRB-Y1bAnti-Trastuzu*ab Antibodies (AY1b) (recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA; Neutralizing assay; Indirect ELISA

>> Click to learn more core reagents accelerating ADC’s development!
Antibody-Drug Conjugates (ADCs): the Magic Bullets for Treatment

References

1. Gorovits, B. et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5, 997–1006 (2013).

2. Qin, Q. & Gong, L. Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices. Molecules 27, 1–17 (2022).

ACRO Quality

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap